Navigation Links
Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
Date:11/9/2007

lf, said Dr. Becker, also a professor of Pediatrics at the University of Pittsburgh School of Medicine.

In type 1 diabetes, a persons own immune cells destroy the beta cells of the pancreas. Beta cells sense blood glucose and produce insulin, which regulates glucose and turns it into energy. This attack on beta cells begins well before a person develops diabetes and continues long after the disease is diagnosed. Scientists dont know what causes the attack, but the result is the insulin production decreases dramatically. When this happen, glucose builds up in the blood, but the bodys cells starve to death.

About 5 to 10 percent of the nearly 21 million people with diabetes have type 1, formerly known as juvenile onset diabetes or insulin-dependent diabetes. Type 1 diabetes tends to arise in children and young adults but also is diagnosed in older people. Patients need three or more insulin injections a day or treatment with an insulin pump to maintain blood glucose control.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Page: 1 2

Related biology news :

1. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
2. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
3. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
4. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
5. Studying component parts of living cells with carbon nanotube cellular probes
6. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
7. Researchers studying how singing bats communicate
8. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
9. Neuronal conduction of excitation without action potentials based on ceramide production
10. To maximize biofuel potential, researchers look for sorghums sweet spot
11. Joslin researchers uncover potential role of leptin in diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED VOICE DIRECTED PAYMENT METHOD AND ... new groundbreaking payment method. Payment accounts may be selected ... be accessed if both the speech (the word associated ...
(Date:2/18/2015)... Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Boston, MA Tuesday, March 3, 2015 ... Investors Conference, Orlando, FL Wednesday, March ... Live Webcasts To access the live webcasts for these events, ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... call; most lack or have only rudimentary vocal cords. A ... and then silently signals her beau. But the female ... of declaring her interest: She emits a high-pitched chirp that ... This is one of several unusual frog-related findings reported ...
... and Java ... ... high-precision biometric identification technologies, today announced,the availability of MegaMatcher 2.1 ... and multi-biometric,face-fingerprint identification systems. MegaMatcher 2.1 includes a number,of new ...
... N.J., May 9 BIO-key International, Inc.,(OTC Bulletin Board: BKYI) ... Thursday, May 15, 2008 before the market opens.,In conjunction with ... broadcast live over the Internet on Thursday, May 15, 2008 ... International, Inc. First Quarter 2008 Earnings Conference ...
Cached Biology News:Female concave-eared frogs draw mates with ultrasonic calls 2Female concave-eared frogs draw mates with ultrasonic calls 3Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems 2Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems 3Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems 4BIO-key(R) Announces First Quarter 2008 Earnings Release and Conference Call Schedule 2
(Date:2/27/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) ... of Trypsin" report to their offering. , ... providing comprehensive data on Trypsin globally and regionally ( ... North America , Latin America ... Trypsin This report focuses on three primary areas; ...
(Date:2/27/2015)... DIEGO , Feb. 27, 2015  Pfenex Inc. ... the development of biosimilar therapeutics, today announced that it ... Francisco Marriott Marquis on March 2 nd at ... participate on a panel discussing the current state of ... of Biosimilars . For more information ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... fiscal first quarter ended December  31, 2014. All figures ... unless otherwise stated. "During the quarter ... existing customers and add to our sales pipeline," said ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Monogram announces availability of HERmark and HER1 and HER3 ... Assays ... June 2 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... on HERmark(TM),the company,s novel oncology assay, as a means ...
... (TSH),Canada,s largest urban community hospital, has selected Chyma(TM) ... The,implementation of Chyma(TM) for their team of more ... departments at the two hospital campuses and will,soon ... "Chyma(TM) reflects the commitment of the Scarborough ...
... 2 The following release was,issued today by Thomas P. ... the New York State Common Retirement Fund, the Lead Plaintiff,in ... UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA ... MCK ) SECURITIES LITIGATION, Master File No. 99-CV-20743 ...
Cached Biology Technology:Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 2Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 3Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 4Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 5Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting 6Canada's Largest Urban Community Hospital Chooses Chyma(TM) On-Call Physician Scheduling Technology 2Notice of Initial Distribution of Net Settlement Funds 2Notice of Initial Distribution of Net Settlement Funds 3
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Anti-Cullin-1 Host: rabbit polyclonal Species Reactivity: human, mouse Applications: IHC(P), WB, IP Storage: 4C...
...
... , Maintenance 112 days/each ... , Immunizations/Boost injections x5 /each ... , Production bleed (25 ml blood ... ~ 100 ml blood (~50 ml serum) x1 each ...
Biology Products: